Dantrolene Sodium side effects: what 1,144 FDA adverse event reports show

Dantrolene Sodium · 58 reaction terms · 670 drug–reaction co-reports · data 2026-09-14

Drug class

Not stated in label

Who reports

1,144 reports · 87% serious · 126 with death outcome · 45% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Dantrolene Sodium for Injection is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Dantrolene Sodium .

FDA label, Indications and Usage

What it is

DESCRIPTION Dantrolene Sodium for Injection, USP is a sterile, non-pyrogenic, lyophilized formulation. Dantrolene Sodium for Injection, USP is supplied in 100 mL vials containing 20 mg dantrol.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 17 strongest signals

Labeled adverse reaction 1Labeled (related wording) 2Likely indication confounding 1Lab value / disease marker 3Not in label — unassessed 10

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 41 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Neuroleptic malignant syndrome	79	122.6 99.0–151.8ROR 131.6 · χ² 9,347 / p <1e-300	118.3 EB05 98.0 · IC025 +5.7 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 80.6	no trial data cached
Muscle spasticity	31	45.9 32.4–65.0ROR 47.2 · χ² 1,315 / p 3e-288	44.6 EB05 32.9 · IC025 +4.1 3/3 methods agree	Not in label — unassessed	serious PRR 36.2	no trial data cached
Muscle rigidity	17	26.1 16.3–41.9ROR 26.5 · χ² 385 / p 4e-86	25.4 EB05 16.7 · IC025 +3.1 3/3 methods agree	Likely indication confounding term in indications	serious PRR 19.3	no trial data cached
Disseminated intravascular coagulation	20	26.0 16.8–40.2ROR 26.4 · χ² 456 / p 2e-101	25.4 EB05 17.3 · IC025 +3.3 3/3 methods agree	Labeled (related wording) related wording	serious PRR 17.1 · ♀ 15% (drug 45%) · 90% clinician	no trial data cached
Blood creatine phosphokinase increased	29	18.2 12.7–26.1ROR 18.6 · χ² 454 / p 4e-101	17.9 EB05 13.0 · IC025 +3.2 3/3 methods agree	Lab value / disease marker	serious PRR 13.3	no trial data cached
Respiratory failure	59	14.8 11.6–19.0ROR 15.6 · χ² 749 / p 3e-165	14.7 EB05 11.7 · IC025 +3.3 3/3 methods agree	Labeled (related wording) related wording	serious PRR 9.8 · 93% clinician	no trial data cached
Gamma-glutamyltransferase increased	17	14.1 8.8–22.5ROR 14.3 · χ² 193 / p 3e-44	13.2 EB05 8.2 · IC025 +2.5 3/3 methods agree	Lab value / disease marker	serious PRR 9.1	no trial data cached
Altered state of consciousness	16	13.6 8.4–22.2ROR 13.8 · χ² 175 / p 3e-40	12.7 EB05 7.6 · IC025 +2.5 3/3 methods agree	Not in label — unassessed	serious PRR 9.0	no trial data cached
Muscle tightness	12	13.6 7.7–23.9ROR 13.7 · χ² 128 / p 6e-30	12.1 EB05 6.5 · IC025 +2.2 3/3 methods agree	Not in label — unassessed	serious PRR 11.5	no trial data cached
Convulsion (seizure)	41	13.0 9.6–17.5ROR 13.4 · χ² 442 / p 2e-98	12.7 EB05 9.6 · IC025 +3.0 3/3 methods agree	Not in label — unassessed	serious PRR 8.6 · 94% clinician	no trial data cached
Rhabdomyolysis (muscle breakdown)	26	11.5 7.8–16.8ROR 11.7 · χ² 238 / p 5e-54	10.8 EB05 7.4 · IC025 +2.6 3/3 methods agree	Not in label — unassessed	serious PRR 7.6 · 92% clinician	no trial data cached
Body temperature increased	11	9.9 5.5–17.7ROR 9.9 · χ² 79 / p 3e-19	8.0 EB05 4.4 · IC025 +1.8 3/3 methods agree	Lab value / disease marker	serious PRR 8.0	no trial data cached
Hyperkalaemia (high potassium)	18	9.5 6.0–15.0ROR 9.6 · χ² 128 / p 6e-30	8.3 EB05 5.3 · IC025 +2.2 3/3 methods agree	Not in label — unassessed	serious PRR 6.4	no trial data cached
Multiple sclerosis relapse	29	7.7 5.4–11.0ROR 7.9 · χ² 163 / p 1e-37	7.0 EB05 5.1 · IC025 +2.2 3/3 methods agree	Not in label — unassessed	serious PRR 6.6 · ♀ 76% (drug 45%)	no trial data cached
Hepatic function abnormal	15	7.4 4.5–12.3ROR 7.5 · χ² 77 / p 8e-19	6.3 EB05 4.0 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 5.3	no trial data cached
Vaginal haemorrhage	10	4.3 2.3–8.0ROR 4.3 · χ² 22 / p 1e-6	3.7 EB05 2.2 · IC025 +0.8 3/3 methods agree	Not in label — unassessed	serious PRR 6.0	no trial data cached
Multiple sclerosis	10	3.8 2.1–7.1ROR 3.8 · χ² 18 / p 1e-5	3.3 EB05 2.0 · IC025 +0.7	Not in label — unassessed	serious PRR 3.4	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Neuroleptic malignant syndrome	79	122.6 99.0–151.8ROR 131.6 · χ² 9,347 / p <1e-300	118.3 EB05 98.0 · IC025 +5.7 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 80.6	no trial data cached
Respiratory failure	59	14.8 11.6–19.0ROR 15.6 · χ² 749 / p 3e-165	14.7 EB05 11.7 · IC025 +3.3 3/3 methods agree	Labeled (related wording) related wording	serious PRR 9.8 · 93% clinician	no trial data cached
Convulsion (seizure)	41	13.0 9.6–17.5ROR 13.4 · χ² 442 / p 2e-98	12.7 EB05 9.6 · IC025 +3.0 3/3 methods agree	Not in label — unassessed	serious PRR 8.6 · 94% clinician	no trial data cached
Muscle spasticity	31	45.9 32.4–65.0ROR 47.2 · χ² 1,315 / p 3e-288	44.6 EB05 32.9 · IC025 +4.1 3/3 methods agree	Not in label — unassessed	serious PRR 36.2	no trial data cached
Multiple sclerosis relapse	29	7.7 5.4–11.0ROR 7.9 · χ² 163 / p 1e-37	7.0 EB05 5.1 · IC025 +2.2 3/3 methods agree	Not in label — unassessed	serious PRR 6.6 · ♀ 76% (drug 45%)	no trial data cached
Blood creatine phosphokinase increased	29	18.2 12.7–26.1ROR 18.6 · χ² 454 / p 4e-101	17.9 EB05 13.0 · IC025 +3.2 3/3 methods agree	Lab value / disease marker	serious PRR 13.3	no trial data cached
Rhabdomyolysis (muscle breakdown)	26	11.5 7.8–16.8ROR 11.7 · χ² 238 / p 5e-54	10.8 EB05 7.4 · IC025 +2.6 3/3 methods agree	Not in label — unassessed	serious PRR 7.6 · 92% clinician	no trial data cached
Disseminated intravascular coagulation	20	26.0 16.8–40.2ROR 26.4 · χ² 456 / p 2e-101	25.4 EB05 17.3 · IC025 +3.3 3/3 methods agree	Labeled (related wording) related wording	serious PRR 17.1 · ♀ 15% (drug 45%) · 90% clinician	no trial data cached
Hyperkalaemia (high potassium)	18	9.5 6.0–15.0ROR 9.6 · χ² 128 / p 6e-30	8.3 EB05 5.3 · IC025 +2.2 3/3 methods agree	Not in label — unassessed	serious PRR 6.4	no trial data cached
Gamma-glutamyltransferase increased	17	14.1 8.8–22.5ROR 14.3 · χ² 193 / p 3e-44	13.2 EB05 8.2 · IC025 +2.5 3/3 methods agree	Lab value / disease marker	serious PRR 9.1	no trial data cached
Muscle rigidity	17	26.1 16.3–41.9ROR 26.5 · χ² 385 / p 4e-86	25.4 EB05 16.7 · IC025 +3.1 3/3 methods agree	Likely indication confounding term in indications	serious PRR 19.3	no trial data cached
Altered state of consciousness	16	13.6 8.4–22.2ROR 13.8 · χ² 175 / p 3e-40	12.7 EB05 7.6 · IC025 +2.5 3/3 methods agree	Not in label — unassessed	serious PRR 9.0	no trial data cached
Hepatic function abnormal	15	7.4 4.5–12.3ROR 7.5 · χ² 77 / p 8e-19	6.3 EB05 4.0 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 5.3	no trial data cached
Muscle tightness	12	13.6 7.7–23.9ROR 13.7 · χ² 128 / p 6e-30	12.1 EB05 6.5 · IC025 +2.2 3/3 methods agree	Not in label — unassessed	serious PRR 11.5	no trial data cached
Body temperature increased	11	9.9 5.5–17.7ROR 9.9 · χ² 79 / p 3e-19	8.0 EB05 4.4 · IC025 +1.8 3/3 methods agree	Lab value / disease marker	serious PRR 8.0	no trial data cached

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Muscle spasticity — n=31, PRR 45.9
Convulsion — n=41, PRR 13.0
Rhabdomyolysis — n=26, PRR 11.5
Multiple sclerosis relapse — n=29, PRR 7.7

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Dantrolene?

In FDA FAERS, the most frequently co-reported reaction terms for Dantrolene are neuroleptic malignant syndrome, respiratory failure, convulsion, muscle spasticity, multiple sclerosis relapse, blood creatine phosphokinase increased. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Dantrolene have an FDA boxed warning?

No. The FDA label retrieved for Dantrolene has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Dantrolene causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID ab0efc75-0598-4f4e-91ad-6195bb2661fe, effective 20241211; matched on openfda.generic_name.exact:"DANTROLENE")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 58 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.